The key to treating cancer could be the body's own immune system

Melanoma
(Image credit: Joe Raedle/Getty Images)

A new study in The New England Journal of Medicine, presented this weekend at the American Society of Clinical Oncology's annual conference in Chicago, found that two cancer drugs, when taken together, could shrink tumors in patients with advanced-stage melanoma.

In a trial of 945 worldwide patients, researchers found that combining ipilimumab and nivolumab, two drugs that work with the body's immune system, reduced the melanoma tumors of nearly 60 percent of patients. The combination, which spurred the immune system to fight cancer, also prevented melanoma from advancing for almost a year in more than half of the patients studied.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Meghan DeMaria

Meghan DeMaria is a staff writer at TheWeek.com. She has previously worked for USA Today and Marie Claire.